Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola
→ Ten months after Array showed off the positive BEACON-CRC data that enticed Pfizer to write a $11.4 billion buyout check, the pharma giant has officially bagged the OK. Braftovi is now approved (in combination with Erbitux, or cetuximab) to treat BRAF V600E-mutant metastatic colorectal cancer. An estimated 15% of all patients with metastatic colorectal cancer harbor BRAF mutations, which represent a poor prognosis. In a Phase III trial, the targeted therapy induced a median OS of 8.4 months versus 5.4 months for control (p=0.0003).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.